Application of pheretima protein peptide in preparation of drugs for preventing and/or treating thrombotic diseases

A technology of ground dragon protein peptide and thrombotic disease, applied in the application field of medicine, can solve the problems of unsatisfactory treatment effect and single treatment effect, achieve good anticoagulant effect, anticoagulant fibrinolysis, and prevent and treat thrombosis effect of disease

Active Publication Date: 2020-03-31
中食都庆(山东)生物技术有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these drugs have a certain effect, the therapeutic effect is single and the therapeutic effect is not ideal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pheretima protein peptide in preparation of drugs for preventing and/or treating thrombotic diseases
  • Application of pheretima protein peptide in preparation of drugs for preventing and/or treating thrombotic diseases
  • Application of pheretima protein peptide in preparation of drugs for preventing and/or treating thrombotic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The separation and purification of embodiment 1 earthworm protein peptide

[0045] The separation and purification steps of the earthworm protein peptide include the following steps:

[0046] 1) 10 g of earthworm peptide (provided by Zhongshi Duqing (Shandong) Biological Co., Ltd.), was added to 200 mL of 2% acetic acid aqueous solution and stirred for 0.5 h to dissolve. The ground dragon protein peptide was centrifuged at 8000r / min, 15°C for 15min, filtered through a filter head with a pore size of 0.45μm, and then used for later use.

[0047] 2) Separation of Sephadex G50 chromatographic column: First, wash the column with ultrapure water for 3 to 5 column volumes and load the sample, then wash the column with ultrapure water at 2.5mL / min for 2 hours, and the terrapin peptide after passing through the membrane is separated according to the chromatographic peak Fractions were collected and each fraction was concentrated and then freeze-dried in a vacuum dryer into a p...

Embodiment 2

[0056] 1) Determination of basic physical and chemical properties of earthworm protein peptide

[0057] Determination of protein content (GB5009.9-Kjeldahl nitrogen analyzer), determination of moisture content (GB5009.3), determination of ash content (GB5009.4), the measurement results are shown in Table 1.

[0058] Table 1 Determination results of basic physicochemical properties of earthworm protein peptide

[0059] protein moisture Ash 75.7％ 5.29％ 5.1％

[0060] 2) Analysis of amino acid distribution in earthworm protein peptide

[0061] The amino acid composition of Dilong protein peptide was analyzed by Hitachi L-8900 amino acid automatic analyzer. The analysis results are detailed in Figure 7 . Depend on Figure 7 The distribution of the amino acid composition of the earthworm protein peptide can be known.

[0062] 3) Determination of molecular weight distribution of earthworm protein peptide

[0063] The molecular weight distribution of Di...

Embodiment 3

[0064] Example 3 Inhibitory Effect of Dilongin Peptide on Carrageenan-Induced Tail Thrombosis in Rats

[0065] 1) Reagents and instruments

[0066] Carrageenan was provided by Sagma; vernier caliper; stopwatch; scalpel, dilongin peptide, yellow powder, provided by Zhongshi Duqing (Shandong) Biological Co., Ltd., aspirin, white flake, batch number H51021360, BAIOO Lumbrokinase capsules, yellow capsules, batch number H11021129, lidocaine hydrochloride injection, injection, batch number H37022147.

[0067] 2) Modeling method

[0068] Take carrageenan, and be mixed with 0.9%NaCl concentration and be 2mg / mL carrageenan solution (2%); Give weight to rat, inject carrageenan subcutaneously in rat, dosage is 80mg / kg, The prevention group was given intragastric administration 5 days in advance, and 30 minutes after modeling, the other 4 groups except the prevention group were given intragastric administration according to the relevant dose, and then the rats were placed in a constant ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
absorbanceaaaaaaaaaa
Login to view more

Abstract

The invention provides an application of pheretima protein peptide in preparation of drugs for preventing and/or treating thrombotic diseases, and belongs to the technical field of prevention and treatment of cardiovascular and cerebrovascular diseases. The pheretima protein peptide is one or more selected from the group consisting of Leu-Val-Thr-Leu-Gly-Asn-Glu, Leu-Leu-Ala-Pro-Pro, Leu-Leu-Pro-Ala-Pro and Thr-Val-Ala-Pro-Phe. The pheretima protein peptide provided by the invention can significantly inhibit thrombin activity, thereby achieving the effect of anticoagulation; in vivo, the pheretima protein peptide provided by the invention has a significant inhibitory effect on carrageenan-induced tail thrombosis in rats; and in vitro and in vivo of thrombus rats, the pheretima protein peptide provided by the invention exhibits a good anticoagulant effect. The pheretima protein peptide provided by the invention has the functions of inhibiting thrombosis, realizing thrombolysis and anticoagulation and promoting fibrinolysis, and can effectively prevent and treat the thrombotic diseases.

Description

technical field [0001] The present invention relates to the technical field of prevention and treatment of cardiovascular and cerebrovascular diseases, in particular to the application of dilongin peptide in the preparation of medicines for preventing and / or treating thrombotic diseases. Background technique [0002] The diseases caused by the two pathological processes of thrombosis and thromboembolism are clinically called thrombotic diseases. Thrombotic disease is a serious threat to human life and health, and its incidence rate ranks first among various diseases, and it has gradually increased in recent years. It is one of the focuses and hotspots of contemporary medical research. [0003] Traditional antithrombotic drugs mainly include anticoagulant drugs, antiplatelet drugs and thrombolytic drugs. Although these drugs have certain effects, the therapeutic effect is single and the therapeutic effect is not ideal. Contents of the invention [0004] The object of the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61P7/02
CPCA61K38/08A61P7/02A61K38/07
Inventor 张九勋张学军田明展张西平魏玮
Owner 中食都庆(山东)生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap